This study aimed to validate PKCδ as a prognostic biomarker and investigate its mechanistic contributions to therapeutic resistance.<h4>Methods</h4>Immunohistochemistry (IHC) was used to analyze the expression of PKCδ in 200 DLBCL tissues to validate the correlation between PKCδ and therapeutic efficacy as well as prognosis. This evidence concerns the gene PRKCD and diffuse large B-cell lymphoma.